273 related articles for article (PubMed ID: 35215916)
21. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
22. Impact of the Delta variant on vaccine efficacy and response strategies.
Bian L; Gao Q; Gao F; Wang Q; He Q; Wu X; Mao Q; Xu M; Liang Z
Expert Rev Vaccines; 2021 Oct; 20(10):1201-1209. PubMed ID: 34488546
[TBL] [Abstract][Full Text] [Related]
23. How do vaccinated people spread Delta? What the science says.
Subbaraman N
Nature; 2021 Aug; 596(7872):327-328. PubMed ID: 34385613
[No Abstract] [Full Text] [Related]
24. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021.
Naleway AL; Groom HC; Crawford PM; Salas SB; Henninger ML; Donald JL; Smith N; Thompson MG; Blanton LH; Bozio CH; Azziz-Baumgartner E
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(46):1608-1612. PubMed ID: 34793417
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome.
Salto-Alejandre S; Berastegui-Cabrera J; Camacho-Martínez P; Infante-Domínguez C; Carretero-Ledesma M; Crespo-Rivas JC; Márquez E; Lomas JM; Bueno C; Amaya R; Lepe JA; Cisneros JM; Pachón J; Cordero E; Sánchez-Céspedes J;
Sci Rep; 2021 Jun; 11(1):12931. PubMed ID: 34155307
[TBL] [Abstract][Full Text] [Related]
27. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution.
Baj A; Novazzi F; Genoni A; Ferrante FD; Taborelli S; Pini B; Partenope M; Valli M; Gasperina DD; Capuano R; Prestia M; Spezia PG; Azzi L; Focosi D; Maggi F
Emerg Microbes Infect; 2021 Dec; 10(1):1254-1256. PubMed ID: 34110974
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant.
Sentis C; Billaud G; Bal A; Frobert E; Bouscambert M; Destras G; Josset L; Lina B; Morfin F; Gaymard A; The Covid-Diagnosis Hcl Study Group
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632661
[TBL] [Abstract][Full Text] [Related]
29. Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines.
de Souza WM; Muraro SP; Souza GF; Amorim MR; Sesti-Costa R; Mofatto LS; Forato J; Barbosa PP; Toledo-Teixeira DA; Bispo-Dos-Santos K; Parise PL; Brunetti NS; Moreira JCO; Costa VA; Cardozo DM; Moretti ML; Barros-Mazon S; Marchesi GF; Ambrosio C; Spilki FR; Almeida VC; Vieira AS; Zambon L; Farias AS; Addas-Carvalho M; Benites BD; Marques RE; Sabino EC; Zuben ABV; Weaver SC; Faria NR; Granja F; Angerami RN; Proença-Módena JL
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834934
[TBL] [Abstract][Full Text] [Related]
30. Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant.
Cocherie T; Bastide M; Sakhi S; Zafilaza K; Flandre P; Leducq V; Jary A; Burrel S; Louet M; Calvez V; Marcelin AG; Marot S
Microbiol Spectr; 2022 Oct; 10(5):e0192222. PubMed ID: 36125269
[TBL] [Abstract][Full Text] [Related]
31. An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward.
Wi YM; Kim SH; Peck KR
J Korean Med Sci; 2022 Jan; 37(4):e28. PubMed ID: 35075827
[TBL] [Abstract][Full Text] [Related]
32. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
33. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
[TBL] [Abstract][Full Text] [Related]
34. The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers' unvaccinated household members.
Salo J; Hägg M; Kortelainen M; Leino T; Saxell T; Siikanen M; Sääksvuori L
Nat Commun; 2022 Mar; 13(1):1162. PubMed ID: 35246536
[TBL] [Abstract][Full Text] [Related]
35. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
37. Molecular and Serological Characterization of the SARS-CoV-2 Delta Variant in Bangladesh in 2021.
Ghosh AK; Kaiser M; Molla MMA; Nafisa T; Yeasmin M; Ratul RH; Sharif MM; Akram A; Hosen N; Mamunur R; Amin MR; Islam A; Hoque ME; Landt O; Lytton SD
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835116
[TBL] [Abstract][Full Text] [Related]
38. Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo.
Tani-Sassa C; Iwasaki Y; Ichimura N; Nagano K; Takatsuki Y; Yuasa S; Takahashi Y; Nakajima J; Sonobe K; Nukui Y; Takeuchi H; Tanimoto K; Tanaka Y; Kimura A; Tohda S
J Med Virol; 2022 Apr; 94(4):1707-1710. PubMed ID: 34825717
[TBL] [Abstract][Full Text] [Related]
39. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
